Sun Pharma’s specialty portfolio, Organon deal to drive growth
Sun Pharmaceutical pursued an acquisition for FY27.
· Economic Times Markets, ET Stocks
Sun Pharmaceutical achieved notable revenue growth in the September quarter, driven by strong performance in India and specialty medicines. The company anticipates medium-term growth from therapies like Ilumya and ongoing innovative projects. Although profitability was affected by acquisition and litigation costs, the domestic market share increased to 8.6% from last year.
Key facts
- Period
- FY27
The analysis
Sun Pharmaceutical reported movement of 8.6% for FY27. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is +0.9% on the day at ₹1,777.70, and has returned -11.2% over three months. It sits 11% below its 52-week high. The pharma & healthcare sector has moved -0.9% over the same period, so Sun Pharmaceutical is running 10.3 points behind its peers.
For Sun Pharmaceutical, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Market context
- In focus: Sun Pharmaceutical (SUNPHARMA), in Pharma & Healthcare.
- Over three months: Sun Pharmaceutical -11.2% against Pharma & Healthcare -0.9% (10.3 points behind).
- Trading well above normal today: Sun Pharmaceutical at 3.4 times its 20-day average volume.
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Sun PharmaceuticalSUNPHARMA · Pharma & Healthcare | ₹1,777.70 | +0.9% | -2.1% | -11.2% | -11.2% | 3.4× | — |
Pharma & Healthcare
1M -0.6% · 3M -0.9%
Sun Pharmaceutical
Prices as of 30 Oct 2026, 16:11 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Regulator orders Sun Pharma to shut Assam plant over eye-drop quality lapses; what you should know
Q2 Results Live: Varun Beverages Q3 Net Profit Rises 14% YoY; Reliance Slips, Sun Pharma Gains Ahead Of Earnings
Sun Pharma Q2 profit falls 36% as litigation costs hit earnings
Stocks To Watch Today: Dixon Tech, Syrma SGS, Sun Pharma, Wipro, Trent Among Others
Stocks in news: Reliance Industries, Jio Platforms, M&M, CDSL, ITC, NTPC, IOCL and Hero MotoCorp